We are live on ! Find out more
HTGM

HTG Molecular Diagnostics, Inc. Common Stock
HTGM

Delisted

HTGM was delisted on the 14th of June, 2023.

Back to rankings

21 hedge funds and large institutions have $14.5M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 23 → 21 (-2)

12% less capital invested

Capital invested by funds: $16.4M → $14.5M (-$1.93M)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.4K
2
JP Morgan Chase
JP Morgan Chase
New York
+$116

Top Sellers

Rank Fund Capital Flow
1
CPA
Cowen Prime Advisors
New York
-$511K
2
SC
Samjo Capital
New York
-$340K
3
Millennium Management
Millennium Management
New York
-$90K
4
NCM
Nantahala Capital Management
Connecticut
-$59K
5
Bank of America
Bank of America
North Carolina
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$3.32M – – –
CPA
2
Cowen Prime Advisors
New York
$3.21M -$511K -8,783 -15%
SC
3
Samjo Capital
New York
$3.2M -$340K -5,833 -11%
NCM
4
Nantahala Capital Management
Connecticut
$1.82M -$59K -1,013 -4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.33M -$1.46K -25 -0.1%
WVP
6
Worth Venture Partners
New Jersey
$776K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$296K -$6.35K -109 -2%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$249K – – –
BlackRock
9
BlackRock
New York
$85K +$1.4K +24 +2%
State Street
10
State Street
Massachusetts
$76K – – –
KWA
11
Kellett Wealth Advisors
Ohio
$61K +$55K +944 New
HWM
12
HighMark Wealth Management
Minnesota
$38K – – –
AF
13
Allworth Financial
California
$18K – – –
Morgan Stanley
14
Morgan Stanley
New York
$15K -$6.75K -116 -33%
UBS Group
15
UBS Group
Switzerland
$12K -$2.27K -39 -17%
MIFH
16
Migdal Insurance & Financial Holdings
Israel
$7K -$3.84K -66 -38%
FAG
17
Fortitude Advisory Group
Washington
$2K +$1.4K +24 New
Millennium Management
18
Millennium Management
New York
– -$90K -1,310 Closed
Bank of America
19
Bank of America
North Carolina
– -$19K -278 Closed
TRCT
20
Tower Research Capital (TRC)
New York
– -$11K -166 Closed
IF
21
Ironwood Financial
Arizona
– -$1K -9 Closed
JP Morgan Chase
22
JP Morgan Chase
New York
– +$116 +2 New

HTGM Hedge Fund Activity: Q4 2021 in Review

21 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2021, worth a combined $14.5M — down 12% from $16.4M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of HTGM and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.

The largest buyer was BlackRock, adding an estimated $1.4K. The largest seller was Cowen Prime Advisors, cutting an estimated $511K.

  • 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2021, down from 23 in Q3 2021.
  • Funds reported $14.5M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2021, down 12% quarter-over-quarter.
  • 3 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of -1 holder.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $1.4K added.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2021 was Cowen Prime Advisors, an estimated $511K sold.

Based on aggregated 13F filings for Q4 2021.